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Introduction: An accurate preoperative rectal cancer staging is crucial to the correct man-
agement of the disease. Despite great controversy around this issue, pelvic magnetic
resonance (RM) is said to be the imagiologic standard modality. This work aimed to evalu-
ate  magnetic resonance accuracy in preoperative rectal cancer staging comparing with the
anatomopathological results.
Methods: We  calculated sensibility, speciﬁcity, positive (VP positive) and negative (VP neg-
ative) predictive values for each T and N. We  evaluated the concordance between both
methods of staging using the Cohen weighted K (Kw), and through ROC curves, we evaluated
magnetic resonance accuracy in rectal cancer staging.
Results: 41 patients met the inclusion criteria. We  achieved an efﬁcacy of 43.9% for T and 61%
for  N staging. The respective sensibility, speciﬁcity, positive and negative predictive values
are  33.3%, 94.7%, 33.3% and 94.7% for T1; 62.5%, 32%, 37.0% and 57.1% for T2; 31.8%, 79%,
63.6%  and 50% for T3 and 27.8%, 87%, 62.5% and 60.6% for N. We  obtained a poor concordance
for  T and N staging and the anatomopathological results. The ROC curves indicated that
magnetic resonance is ineffective in rectal cancer staging.
Conclusion: Magnetic resonance has a moderate efﬁcacy in rectal cancer staging and the
major difﬁculty is in differentiating T2 and T3.
©  2015 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. All
rights reserved.
Estadiamento  pré-operatório  do  câncer  do  reto  por  ressonância
magnética:  correlac¸ão  com  estadiamento  anatomopatológicor  e  s  u  m  oalavras-chave:
âncer do reto
Introduc¸ão: Um estadiamento pré-operatório do Câncer do Reto (CR) é essencial na gestão da
doenc¸a.  Apesar de grande controvérsia, a ressonância magnética pélvica (RM) é apontada
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Ressonância magnética pélvica
Acuidade
Sensibilidade
Especiﬁcidade
como modalidade imagiológica standard. Com este trabalho pretendeu-se avaliar a acuidade
da  RM no estadiamento do CR, comparando com os resultados anatomopatológicos da pec¸a
cirúrgica.
Materiais e métodos: Calculou-se a sensibilidade, especiﬁcidade, valor preditivo positivo (VP
positivo) e negativo (VP negativo) para T e N. Avaliou-se a concordância entre ambas as
formas de estadiamento através do valor de K de Cohen ponderado (Kw) e, através de curvas
ROC, avaliou-se a precisão do estadiamento por RM.
Resultados: 41 doentes cumpriram os critérios de inclusão. Obteve-se uma eﬁcácia de 43.9%
para T e 61% para N. Veriﬁcou-se uma sensibilidade, especiﬁcidade, VP positivo e negativo,
respectivamente, de 33.3%, 94.7%, 33.3% e 94.7% para T1, 62.5%, 32%, 37.0% e 57.1% para T2,
31.8%, 79%, 63.6% e 50% para T3, 27.8%, 87%, 62.5% e 60.6% para N. A concordância calculada
foi  pobre para T e N. As curvas ROC indicaram que o estadiamento do CR por RM foi ineﬁcaz.
Conclusão: A RM apresenta acuidade moderada no estadiamento do CR, onde a maior diﬁ-
culdade está na distinc¸ão entre T2-T3.
© 2015 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.
Todos os direitos reservados.Introduction
The incidence and mortality of oncological diseases have
increased at an alarming rate worldwide, and according
to World Health Organization, the incidence of cancer will
increase to 22 million/year in the next two decades.1
In Portugal, colorectal cancer (CRC) is the second most
frequent cancer in both men  and women, with an overall inci-
dence of 14.5% and 15.7% mortality. In 2012, this disease was
appointed as the second leading cause of cancer death in both
genders.2 Rectal cancer (RC), in particular, exhibited in north-
ern region of this country in 2008 an incidence of 24.6/1,00,000
inhabitants; a progressive increase in this value since 1999 was
found. In the district of Braga, its incidence in this year was
16.8/1,00,000 inhabitants.3
RC prognosis has improved greatly in recent decades and
this was mainly due to advances in preoperative staging,
which was reﬂected in the therapeutic approach,4 where a
change was observed, from a purely surgical treatment to a
multidisciplinary approach,5,6 lowering the lower local recur-
rence rate to 11% and improving the survival rate at 5 years to
58%,7 compared to previous values (27 and 48%, respectively).5
Preoperative staging of RC is divided into local and remote
staging.8–10 The information (both clinical and pathological)
gathered from the staging is grouped according to “Tumor-
Node-Metastasis” (TNM) classiﬁcation of the American Joint
Committee on Cancer in different prognostic groups or
anatomical stages.11,12 T and N stages are the best determi-
nants of prognosis, being critical components of preoperative
staging.13 Thus, in addition to the use of a reliable imaging
modality and with high accuracy in preoperative staging of
CR be a crucial prognosis factor,14 this procedure also helps
in choosing the best therapeutic strategy, enabling a bal-
ance between oncological safety and quality of life of the
patient.10,12Nowadays, there are several imaging modalities for preop-
erative staging of RC, including computed tomography (CT),
pelvic magnetic resonance imaging (MRI), endorectal ultra-
sound (EUS), and positron emission tomography (PET).10EUS and MRI  are the main instruments of preoperative
staging.15 However, there is no consensus about the best
method.5,16 Several studies suggest MRI as being superior to
EUS,9,17–20 and therefore MRI  is the routine imaging modality
for preoperative staging of RC.5,21 As to T staging, MRI  shows
an acuity between 55 and 86%; as to N staging, the accuracy
varies from 39 to 95%.5
In RC staging, the main role of MRI lies in the evaluation
of tumors in advanced and occlusive stages.15,22 With respect
to stages T3 and T4, sensitivity and speciﬁcity of 74 and 76%
(for T3) and 82 and 96% (for T4) were observed, respectively.22
For T1 and T2 stages, MRI is less sensitive versus EUS, with no
difference relative to T3 and T4 stages.16
Detection of N is the biggest challenge of any imaging
examination, with 66% sensitivity of MRI in its evaluation and
76% speciﬁcity.5
This study aims to evaluate the accuracy of MR in the pre-
operative staging of RC, compared to the anatomopathological
result of the surgical specimen.
Materials  and  methods
Population
The target population for this study consists of 216 patients
with histological diagnosis of RC treated in the General Surgery
Service, Hospital de Braga (HB) between January 1st, 2007 and
December 31, 2013.
Inclusion criteria for this study were: patients with his-
tological diagnosis of rectal adenocarcinoma; patients with
a conclusive preoperative staging by MRI, and patients
with pathology staging results based on the surgical speci-
men.
Exclusion criteria were the following: patients with a his-
tological diagnosis differing from the above; patients with
a diagnosis of RC who did not undergo MRI  or for whom
such analysis was inconclusive; patients without results from
pathology staging, and patients undergoing primary treat-
ment.
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Table 1 – MR and anatomopathological staging related to
T and N.
RM staging Anatomopathological staging
Frequency (%) Frequency (%)
T0 0 (0) 0 (0)
T1 3 (7.2) 3 (7.2)
T2 27 (65.9) 16 (39.0)
T3 11 (26.8) 22 (53.7)
T4 0 (0) 0 (0)
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Table 2 – Comparison between RM and
anatomopathological staging, related to T.
RM staging
T1 (%) T2 (%) T3 (%) Total (%)
Anatomopathological staging
T1 1 (2.44) 2 (4.88) 0 (0) 3 (7.32)
T2 2 (4.88) 10 (24.4) 4 (9.76) 16 (39.0)
T3 0 (0) 15 (36.6) 7 (17.1) 22 (53.7)N0 36 (87.8) 23 (56.1)
N+ 5 (12.2) 18 (43.9)
ample
 convenience sample of 41 patients who meet inclu-
ion/exclusion criteria previously deﬁned was studied.
ata  collection
linical and staging data collected include: age, gender, onco-
ogical history, tumor location, and T/N staging by means of
RI.
Pathological data comprise the histological type and TNM
taging.
Follow-up data are related to the occurrence of relapse and
eath.
This project was approved by HB’s Ethics Committee and
lso by Ethics Subcommittee for Life and Health Sciences.
tatistical  analysis
he collected data were organized in an Excel (Microsoft®
fﬁce 2010) database, and the Statistical Package for Social
ciences (SPSS) version 22.0 (SPSS Inc., Chicago, IL, USA) was
lso used.
A descriptive analysis of the variables under study, to
rovide frequencies, means and standard deviations, was per-
ormed.
Sensitivity, speciﬁcity, positive and negative predictive val-
es (PV) of RM staging, related to T and N, were compared with
athology results. For this purpose, the online tool MedCalc®
vailable in http://www.medcalc.org/calc/diagnostic test.php,
as used. Efﬁcacy was calculated by the formula
TP + TN/n) and the conﬁdence interval (CI) by the formula:
 − Z ×√P(1 − P)/√n; P + Z ×√P(1 − P)/√N.
The agreement between the staging results obtained
y MRI  and anatomopathological study was assessed by
alculating the value of weighted Cohen’s Kappa (Kw); to
his end, we  used the online tool VassarStats, available in
ttp://vassarstats.net/kappa.html. A value of Kw between 0.00
nd 0.20 indicates poor agreement; between 0.21 and 0.40
eveals a considerable agreement; between 0.41 and 0.60,
oints to a moderate agreement; between 0.61 and 0.80 indi-
ates a good agreement; and between 0.81 and 1.00 shows
xcellent agreement.23
Finally, using SPSS program, we  used ROC curves for a com-
arative study of MRI  and anatomopathological staging, by
eans of area under the curve (AUC) calculation. ROC curve
ith AUC assessment is a good predictor of the accuracy ofTotal 3 (7.32) 27 (65.9) 11 (26.8) 41 (100)
a test. The closer the AUC is to 1, the better the examination
is. Values ≤0.50 represent a poor or ineffective test; between
≥0.70 and <0.80 indicate an test with average or reasonable
accuracy; and values ≥0.80 predict a good or excellent test.24
For all tests, it was assumed a signiﬁcance of 0.05 and a
conﬁdence interval (CI) of 95%.
Results
Sample  characterization
The study population consists of 41 subjects who meet inclu-
sion and exclusion criteria. Of these, 58.5% (n = 24) are male,
aged between 31 and 88 years.
In 12.2% (n = 5) of patients, there is a personal history of
another cancer.
As for tumor localization, 14.6% (n = 6) of the cases are
located in the lower third, 68.3% (n = 28) in the middle third and
17.1% (n = 7) in the upper third of the rectum. Disease recur-
rence was observed in 22% (n = 9) patients. Until August 2014
there were 10 deaths in the study population.
T  staging
Regarding MR tumor staging, 7.32% (n = 3) of the tumors are
classiﬁed as T1, 65.9% (n = 27) are staged as T2 and 26.8% (n = 11)
as T3. With regard to anatomopathological staging of surgical
specimens, 7.32% (n = 3) neoplasms are classiﬁed as T1, 39%
(n = 16) are staged as T2 and 53.7% (n = 22) as T3 (Table 1).
Comparing MR staging versus anatomopathological results
based on surgical specimen (Table 2), we noted substaging in
4.88% of cases (n = 2) staged by MR as T1; overstaging in 4.88%
(n = 2) and substaging in 36.6% (n = 15) of tumors staged by MRI
as T2; and overstaging in 9.76% (n = 4) of patients staged as T3.
The sensitivity of MRI in the preoperative staging of RC rel-
ative to T was calculated, and sensitivities of 33.3% (95% CI,
5.47–88.5) for T1, 62.5% (95% CI, 35.5–84.7) for T2 and 31.8%
(95% CI 13.9–54.9) for T3 were observed. As for speciﬁcity, this
parameter is 94.7% (95% CI 82.2–99.2) for T1, 32% (95% CI,
15–53.5) for T2 and 79% (95% CI 54.4–93.8) for T3. The positive
PV calculated is 33.3% (95% CI 5.47–88.5) for T1, 37.0% (95% CI
19.4–57.6) for T2 and 63.6% (95% CI 30.9–88.9) for T3. In rela-
tion to negative PV, values of 94.7% (95% CI 82.2–99.2) for T1,
57.1% (95% CI 28.9–82.2) for T2 and 50% (95% CI 31.3–68.7) for
T3 were found. RM shows efﬁcacy of 43.9% for T staging, 90.2%
in particular for T1 staging, 43.9% for T2 staging and 53.7.6%
for T3 staging.
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Table 3 – Kw values related to T and N staging.
Kw (95%CI) p
T 0.14 (0–0.38) >0.05
N 0.16 (0–0.42) >0.05
Table 4 – Comparison between RM and
anatomopathological staging, related to N.
RM staging
N0 (%) N+ (%) Total (%)
Anatomopathological staging
N0 20 (48.7) 13 (31.7) 33 (80.5)
N+ 3 (7.31) 5 (12.2) 8 (19.5)The value of Kw for T staging was calculated, in order to
determine the correlation between MR  versus anatomopatho-
logical staging. There is poor agreement between the two
forms of staging: Kw = 0.14 (95% CI, 0–0.38) p > 0.05 (Table 3).
The evaluation of MRI  staging accuracy, by formulating
ROC curves and AUC determination, reveals an AUC value of
0.26 (95% CI, 0.00–0.54), p = 0.18 for T1, 0.46 (95% CI 0.28–0.64),
p = 0.63 for T2 and 0.61 (95% CI, 0.43–0.78), p = 0.24 for T3 (Fig. 1).
Estadiamento  N
With respect to N staging done by MR  and shown in Table 1,
87.8% (n = 36) of all tumors are classiﬁed as N0, and 12.2%
(n = 5) as N+. As to anatomopathological staging of surgical
specimens, 56.1% (n = 23) of the tumors do not have lymph
node involvement; in 26.8% (n = 11) there is a N1 staging, and
9.76% (n = 4), received a N2 staging. In 7.32% (n = 3) of tumors
is not possible to classify N, since the minimum of 12 lymph
nodes were not obtained for the analysis. However, since
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Fig. 1 – ROC curves reTotal 23 (56.1) 18 (43.9) 41 (100)
the analyzed ganglia were metastasized, for the sake of the
statistical analysis these ganglia are considered as being N+.
Thus, the anatomopathological analysis, shown in Table 3,
reveals nodal involvement in 43.9% (n = 18) of cases, and no
such involvement in the remaining 56.1% (n = 23).
Comparing the staging relative to N obtained by RM and by
anatomopathological analysis, a substaging is noted in 31.7%
(n = 13) of cases, and an overstaging in 7.32% (n = 3). Table 4
compares both forms of staging.
M  stagingAs for M staging, 90.2% (n = 37) of patients are staged as M0 and
4.88% (n = 2) as M1; in 4.88% (n = 2) of cases it is not possible to
determine the existence of distant metastases.
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iscussion
 precise preoperative staging of CR is critical for the proper
anagement of this disease, since the therapeutic strategies
hould be individualized.10,12,25 Moreover, this staging is also
 predictor of prognosis.12,26
Therefore, the imaging techniques used in tumor staging
roved to be decisive, and it is extremely important to ascer-
ain their effectiveness.26 EUS and MR  are the main tools of
reoperative staging, but there is no consensus on which is
he best method5,16; however, several studies indicate MR to
e superior to EUS; therefore, MRI  is the standard imaging
odality for preoperative staging of RCs.9,18–20
This study was designed with the aim to determine the
ccuracy of MR  in the preoperative staging process for RC.
With regard to T staging, when comparing the staging
erformed by MR  with the anatomopathological staging, a
ubstaging occurred in 4.88% (n = 2) of cases staged by RM as
eing T1; there was overstaging in 4.88% (n = 2) of patients and
ubstaging in 36.6% (n = 15) of those tumors staged by MRI  as
2 and an overstaging in 9.76% (n = 4) patients staged as T3.
iven that, in general, superﬁcial tumors (T1 and T2) with-
ut metastatic lymph nodes are treated solely with surgery,
hile locally advanced tumors or those with nodal metas-
ases are subjected to primary treatment prior to surgical
ecession,14 an undertreatment occurred in 36.6% (n = 15) of
atients, considering that these subjects were staged as T2,
nd their anatomopathological results showed that actually
hese were T3, and thus did not perform primary therapy.
The largest number of cases of incorrect staging by MRI was
bserved in the distinction between stages T2 and T3. This
ay in part be explained by the presence of a desmoplastic
eaction in peritumoral tissues, making it difﬁcult to distin-
uish between spiculation of perirectal fat, caused simply by
brosis, and that that contains viable tumor cells.13,16,27
As for the 4 patients who  were overstaged by RM as T3,
hen actually these were T2 tumors, these could have been
vertreated. However, that did not happen for reasons unre-
ated to this study.
With respect to the calculation of the MRI sensitivity for T
taging, values of 33.3% for T1, 62.5% for T2, and 31.8% for T3
ere observed. These values are lower than those observed
n several other studies.10,14,22,28 However, Beaumont et al.
btained even smaller values in relation to T1 and T2 stages,
amely: 27% for T1 and 59% for T2.16
The values for speciﬁcity were of 94.7% for T1, 32% for T2
nd 79% for T3. With respect to T1 and T3, the results were
onsistent with the bibliography.10,16 In the case of T2, these
alues were lower than those found in most of the referred
tudies.
The positive PV calculated was 33.3% for T1, 37.0% for T2
nd 63.6% for T3. Regarding negative VP, these values were
4.7% for T1, 57.1% for T2 and 50% for T3. These values were
ower than those observed by Uc¸ar et al. and Akasu et al.,
xcept in the case of negative VP for T1, which was similar
o that calculated by Iannicelli et al.4,19The diagnostic efﬁcacy for tumor staging has been ben-
ﬁted from improvements due to the development of MR
echniques; in early studies, the efﬁciency reached about 60%; 5;3  5(2):77–82 81
currently, this indicator is between 92 and 94% for T stage and
63% for N stage.5 Usually the efﬁciency increases with T stage
and varies, according to some authors, between 67 and 94%
or 55 and 86%.23–29 Efﬁcacy calculated for T stage was 43.9%,
particularly 90.2% for T1, 43.9% for T2, and 53.7% for T3. The
results for T in general and for T2 and T3 were lower than
those found by other authors.4,19,23,25 The effectiveness for T1
stage was similar that in another study.4
N detection is the most challenging detection of any imag-
ing examination.5 The criterion “size” for detection of lymph
node metastases is a poor predictor, since non-tumor enlarged
nodes can exist, and the reverse is also true.29 The irregular
contour and heterogeneous signal intensity are more  speciﬁc
criteria for metastazisation.4,17,29
In this study there was substaging in 31.7% (n = 13) of cases
classiﬁed as N0, and overstaging in 7.32% (n = 3); in 31.7%
(n = 13), undertreatment of substaged patients occurred.
The sensitivity, speciﬁcity, positive VP and VP negative rel-
ative to N were 27.8%, 87%, 62.5% and 60.6%, respectively.
The value for sensitivity was lower than those found in sev-
eral previous studies; however, the speciﬁcity showed values
higher than those found in these same studies.5,10,13,14,16,19
Positive and negative VPs were similar to those obtained
in other studies.16,19 The effectiveness of MR  for N staging
was 61%, a ﬁgure similar to that found by several authors,
varying between 39 and 95%.5,14,16,19 The agreement between
the staging results obtained by MR  and anatomopathologi-
cal results, evaluated by Kw value for T and N, were given
as: Kw = 0.14, p < 0.05 and Kw = 0.16, p < 0.05, respectively. These
ﬁgures revealed a poor agreement between the two staging
forms; additionally, they differ from most studies consulted,
where Kw values between 0.71 and 0.89 for T and between 0:40
to 0:56 to N were obtained.4,14,19 The study by Tytherleigh MG
et al. was that that obtained the closest values to ours, namely:
0:37 (p < 0.001) for T staging and 0.25 (p < 0.002) for N staging.30
The evaluation of MR accuracy through ROC curves with
AUC determination showed values for AUC of 0.26, p = 0.18
for T1, 0.46, p = 0.63 for T2, 0.61, p = 12.24 for T3, and 0.40,
p = 0.40 for N staging. Thus, RM proved to be an ineffective
or poor method for N staging. These values were discordant
with those found by other authors, ranging from 0.81 to 0.94
for T staging and from 0.57 to 0.78 for N staging.8
This study has some limitations, such as the relatively
small number of patients, particularly those staged as T1.
There are also biases associated with retrospective studies,
such as selection bias, and the results should be validated
by future prospective multicenter studies. MR  and anato-
mopathological staging were not always made by the same
radiologist and pathologist; this may be an error factor.
In addition, RM began operating in RC staging in HB in
2007. As in any modality, there is a learning curve associated
with this imaging technique, and this may have contributed
to some of the reported staging errors.
Finally, publication bias may be another reason for the dis-
parate results found in most of the literature.Conclusion
RC is a common disease, and its preoperative staging remains
a topic of great concern and controversy. In this study, we
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evaluated the accuracy of MR  in the preoperative staging
of RC, compared to anatomopathological results of surgical
specimens.
MR showed a moderate acuity in RC staging, with efﬁcacy
values between 43.9 and 90.2% for T staging and 61% for N
staging. RM was more  sensitive for T2 stage and more  speciﬁc
for T1 and N+ stages. This imaging modality revealed little
sensitivity to both T1 and N+ (33.3 and 27.8%, respectively),
being more  useful for exclusion, than to conﬁrm these stages.
Most staging errors occurred on the distinction between T2
and T3 stages, resulting in cases of undertreatment.
The agreement between values obtained by MR and anato-
mopathological results was poor for both T and N stages. Thus,
in this study, it was an ineffective or poor method for RC stag-
ing.
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